Aviva’s Burning Rock Biotech BNR Stock Holding History

Aviva’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,480	Closed	-$265K	–	1024
2021 Q3	$265K	Buy	+1,480	New	+$329K	﹤0.01%	976

Other funds holding BNR

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Aviva's BNR Position: Q4 2021 in Review

Aviva sold out of Burning Rock Biotech (BNR) in Q4 2021, closing a stake of 1,480 shares — an estimated $265K sold.

Aviva first reported a position in BNR in Q3 2021 and held it in 1 quarter. The position peaked at $265K in Q3 2021. 62 funds tracked by Wall St. Rank hold BNR as of Q4 2021.

Aviva reported no remaining Burning Rock Biotech position as of Q4 2021 after selling out during the quarter.
Aviva sold 1,480 Burning Rock Biotech shares in Q4 2021, an estimated $265K.
Aviva first reported a position in Burning Rock Biotech in Q3 2021 and held it in 1 quarter.
Aviva's Burning Rock Biotech position peaked at $265K in Q3 2021.
62 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2021.

Based on Aviva's 13F filing for Q4 2021, filed 10 Feb 2022.